NEW YORK and ANN ARBOR, Mich., Oct. 6, 2015 /PRNewswire/ — Lycera Corp., a privately held biopharmaceutical company developing breakthrough immune modulatory medicines, announced today the appointment of Alex G. Howarth as Chief Financial Officer. With over 25 years of experience in healthcare and financial advisory roles, Mr. Howarth brings to Lycera a distinguished track record… Read More

Transformational collaboration will focus on the advancement of Lycera’s innovative pipeline, including Lycera’s first-in-class RORgamma agonists for cancer immunotherapy, and clinical-stage candidate, LYC-30937, being studied for inflammatory bowel disease (IBD) NEW YORK and ANN ARBOR, Mich., June 9, 2015 /PRNewswire/ — Lycera Corp., a privately held biopharmaceutical company developing breakthrough immune modulatory medicines announced today the… Read More

NEW YORK and ANN ARBOR, Mich., April 30, 2015 /PRNewswire/ — Lycera Corp., a biopharmaceutical company developing breakthrough immunomodulatory medicines to treat autoimmune diseases and cancer, today announced the initiation of a Phase 1 clinical trial of LYC-30937 in healthy volunteers.  LYC-30937 is an oral gut-directed ATPase modulator that is being studied for the treatment… Read More

Novel oral RORγ agonists demonstrate anti-tumor efficacy in the 4T1 breast cancer model… Read More